Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)
McGill University Health Centre/Research Institute of the McGill University Health Centre
McGill University Health Centre/Research Institute of the McGill University Health Centre
Swiss Cancer Institute
M.D. Anderson Cancer Center
Gustave Roussy, Cancer Campus, Grand Paris
H. Lee Moffitt Cancer Center and Research Institute
PrECOG, LLC.
Shanghai Pulmonary Hospital, Shanghai, China
University of Iowa
Wake Forest University Health Sciences
Hunan Province Tumor Hospital
Jonsson Comprehensive Cancer Center
UNICANCER
M.D. Anderson Cancer Center
Hackensack Meridian Health
University of Michigan Rogel Cancer Center
Massachusetts General Hospital
Intergroupe Francophone de Cancerologie Thoracique
Fundación GECP
Wake Forest University Health Sciences
M.D. Anderson Cancer Center
Second Affiliated Hospital of Nanchang University
University Medical Center Groningen
Tianjin Medical University Cancer Institute and Hospital
University of Pittsburgh
Dana-Farber Cancer Institute
Beijing Cancer Prevention & Treatment Society
Abramson Cancer Center at Penn Medicine
Fundación GECP
Sun Yat-sen University
University Health Network, Toronto
Rutgers, The State University of New Jersey
Mario Negri Institute for Pharmacological Research
Università Vita-Salute San Raffaele
H. Lee Moffitt Cancer Center and Research Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Mayo Clinic
Fundación GECP
Fundación GECP
Intergroupe Francophone de Cancerologie Thoracique
Washington University School of Medicine
Memorial Sloan Kettering Cancer Center
Weill Medical College of Cornell University
NRG Oncology
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Latin American Cooperative Oncology Group
University of Alabama at Birmingham
University Hospital, Essen
University Health Network, Toronto
Fudan University
Alliance for Clinical Trials in Oncology